Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD
Kathleen E. Corey, Rebecca Pitts, Michelle Lai, et al.
Journal of Hepatology (2021) Vol. 76, Iss. 1, pp. 25-33
Open Access | Times Cited: 56

Showing 1-25 of 56 citing articles:

Impact of non-invasive biomarkers on hepatology practice: Past, present and future
Quentin M. Anstee, Laurent Castéra, Rohit Loomba
Journal of Hepatology (2022) Vol. 76, Iss. 6, pp. 1362-1378
Open Access | Times Cited: 148
Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study
Yasaman Vali, Jenny Lee, Jérôme Boursier, et al.
˜The œLancet. Gastroenterology & hepatology (2023) Vol. 8, Iss. 8, pp. 714-725
Open Access | Times Cited: 94
A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures
Olivier Govaere, Megan Hasoon, Leigh Alexander, et al.
Nature Metabolism (2023) Vol. 5, Iss. 4, pp. 572-578
Open Access | Times Cited: 79
Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH)
Shuang Wang, Scott L. Friedman
Science Translational Medicine (2023) Vol. 15, Iss. 716
Open Access | Times Cited: 52
The Proteomics of MASLD Progression: Insights From Functional Analysis to Drive the Development of New Therapeutic Solutions
Carlos J. Pirola, Tomas Fernández Gianotti, Silvia Sookoian
Alimentary Pharmacology & Therapeutics (2025)
Closed Access | Times Cited: 1
Sulforaphane Ameliorates Nonalcoholic Fatty Liver Disease Induced by High-Fat and High-Fructose Diet via LPS/TLR4 in the Gut–Liver Axis
Ye Xu, Xianghui Huang, Bingxin Huangfu, et al.
Nutrients (2023) Vol. 15, Iss. 3, pp. 743-743
Open Access | Times Cited: 20
Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study
Laura Valenzuela‐Vallejo, Pavlina Chrysafi, Matina Kouvari, et al.
Metabolism (2023) Vol. 148, pp. 155694-155694
Closed Access | Times Cited: 18
ChREBP is activated by reductive stress and mediates GCKR-associated metabolic traits
Charandeep Singh, Byungchang Jin, Nirajan Shrestha, et al.
Cell Metabolism (2023) Vol. 36, Iss. 1, pp. 144-158.e7
Closed Access | Times Cited: 15
Plasma proteomic signature of fatty liver disease: The Rotterdam Study
Yasir J. Abozaid, Ibrahim Ayada, Laurens A. van Kleef, et al.
Hepatology (2023) Vol. 78, Iss. 1, pp. 284-294
Closed Access | Times Cited: 14
KASL Clinical Practice Guidelines for Noninvasive Tests to Assess Liver Fibrosis in Chronic Liver Disease
Mi Na Kim, Ji Won Han, Jihyun An, et al.
Clinical and Molecular Hepatology (2024) Vol. 30, Iss. Suppl, pp. S5-S105
Open Access | Times Cited: 5
3D microperfusion of mesoscale human microphysiological liver models improves functionality and recapitulates hepatic zonation
Milan Finn Wesseler, Nayere Taebnia, Sean Harrison, et al.
Acta Biomaterialia (2023) Vol. 171, pp. 336-349
Open Access | Times Cited: 11
Secreted ADAMTS-like proteins as regulators of connective tissue function
Nandaraj Taye, Charlene Redhead, Dirk Hubmacher
AJP Cell Physiology (2024) Vol. 326, Iss. 3, pp. C756-C767
Closed Access | Times Cited: 4
Association between triglyceride glucose-body mass index and the staging of non-alcoholic steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease
Fan Zhang, Yan Han, Yunfei Wu, et al.
Annals of Medicine (2024) Vol. 56, Iss. 1
Open Access | Times Cited: 4
Efficacy of Non-invasive Biomarkers in Diagnosing Non-alcoholic Fatty Liver Disease (NAFLD) and Predicting Disease Progression: A Systematic Review
Sheenam Garg, Mansey Varghese, F Shaik, et al.
Cureus (2025)
Open Access
Circulating causal protein networks linked to future risk of myocardial infarction
Sean Bankier, Valborg Guðmundsdóttir, Þórarinn Jónmundsson, et al.
medRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
The hepatocellular model of fatty liver disease: from current imaging diagnostics to innovative proteomics technologies
Renee Hernandez, Natasha S. Garcia-Rodriguez, Marco A. Arriaga, et al.
Frontiers in Medicine (2025) Vol. 12
Open Access
Afamin and Apolipoprotein F Associated With Liver Steatosis From People Living With HIV: A Discovery Study
Mario Frías, Eduardo Chicano‐Gálvez, Antonio Rivero‐Juárez, et al.
Alimentary Pharmacology & Therapeutics (2025)
Closed Access
Protein-metabolite association studies identify novel proteomic determinants of metabolite levels in human plasma
Mark D. Benson, Aaron S. Eisman, Usman A. Tahir, et al.
Cell Metabolism (2023) Vol. 35, Iss. 9, pp. 1646-1660.e3
Open Access | Times Cited: 10
Non‐invasive candidate protein signature predicts hepatic venous pressure gradient reduction in cirrhotic patients after sustained virologic response
Shola M. Richards, Fang Guo, Heng Zou, et al.
Liver International (2023) Vol. 43, Iss. 9, pp. 1984-1994
Open Access | Times Cited: 9
Emerging roles for the ADAMTS-like family of matricellular proteins in cardiovascular disease through regulation of the extracellular microenvironment
Karoline Bjarnesdatter Rypdal, Suneel Apte, Ida G. Lunde
Molecular Biology Reports (2024) Vol. 51, Iss. 1
Open Access | Times Cited: 3
Plasma ALS and Gal-3BP differentiate early from advanced liver fibrosis in MASLD patients
David Pérez Compte, Lucas Etourneau, Anne-Marie Hesse, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 3
SomaLogic proteomics reveals new biomarkers and provides mechanistic, clinical insights into Acetyl coA Carboxylase (ACC) inhibition in Non-alcoholic Steatohepatitis (NASH)
Pitchumani Sivakumar, Michelle Saul, Douglas S. Robinson, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 3
MASLD biomarkers: Are we facing a new era?
Douglas Maya‐Miles, Javier Ampuero, David Martí‐Aguado, et al.
Gastroenterología y Hepatología (2024) Vol. 47, Iss. 4, pp. 393-396
Closed Access | Times Cited: 2
Spatial and Single‐Cell Transcriptomics Reveals the Regional Division of the Spatial Structure of MASH Fibrosis
Jinzhong Li, Liu Yang, Maggie Z. X. Xiao, et al.
Liver International (2024)
Open Access | Times Cited: 2
ADAMTSL2 mutations determine the phenotypic severity in Geleophysic Dysplasia
Vladimir Camarena, Monique Williams, Alejo A. Morales, et al.
JCI Insight (2024)
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top